Figure 1: NHL incidence rates by time since ART start in men and women across regions.
Incidence rates are predicted for adults with a current CD4 cell count of 450 cells/μl who started an NNRTI-based first-line ART regimen between 2008–2014 at the age of 40 years (model 1). ART, antiretroviral therapy; NHL, non-Hodgkin Lymphoma; NNRTI, non-nucleoside reverse-transcriptase inhibitor; pys, person-years.